Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Oligoscience Biotechnology GmbH operates within the Biotechnology & Pharmaceuticals technology area, where it currently has 2 pending office actions. These 2 pending office actions are spread across 2 distinct examiners and 2 distinct art units. This distribution indicates a diverse prosecution landscape for the company's current intellectual property assets.
The busiest examiner for this company is CHOWDHURY, IQBAL HOSSAIN, who is currently handling 1 pending office action. Since there are 2 pending office actions in total, the workload is divided between the 2 distinct examiners. The involvement of 2 distinct art units suggests that the company's patent applications cover different technical sub-sectors within the broader Biotechnology & Pharmaceuticals field.
From a practitioner's perspective, managing 2 pending office actions across 2 distinct art units requires a strategy that accounts for different technical standards. Each of the 2 distinct examiners may have different interpretations of patentability. The presence of CHOWDHURY, IQBAL HOSSAIN as one of the examiners highlights the need for specialized responses tailored to the specific requirements of the 1 pending office action he manages.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHOWDHURY, IQBAL HOSSAIN | 1 | 73.7% | +57.4% |
| OLSON, ANDREA STEFFEL | 1 | 62.3% | -11.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18497736 | MICROORGANISM FOR PRODUCING HUMAN MILK OLIGOSACCHARIDE | CHOWDHURY, IQBAL HOSSAIN | — |
| Art Unit | Apps |
|---|---|
| 1656 | 1 |
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18497736 | MICROORGANISM FOR PRODUCING HUMAN MILK OLIGOSACCHARIDE | CHOWDHURY, IQBAL HOSSAIN | 1656 | §103 | Non-Final OA | — | Pending | Oct 30, 2023 |
| 17130195 | USE OF HUMAN MILK OLIGOSACCHARIDES IN CALVES FATTENING | OLSON, ANDREA STEFFEL | 1693 | §103 | Final Rejection | 36d | Pending | Dec 22, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial